It is known that hydralazine may protect diabetic kidney disease (DKD) patients by inhibiting reactive oxygen species (ROS) through inhibiting xanthine oxidase (XO), consequently stimulating Nrf2-mediated heme oxygenase 1 (HO-1) [150]. Here, XDH is linked to diabetic kidney disease.